|Brand Name:||Alisken Plus|
|Generic:||Aliskiren hemifumarate + Hydrochlorothiazide|
|Weight:||150 mg+12.5 mg|
|Therapeutic Class:||Combined antihypertensive preparations|
|Manufacturer:||Square Pharmaceuticals Ltd.|
|Last Updated:||2020-11-20 18:15:00|
Alisken Plus Tablet contains Aliskiren hemifumarate + Hydrochlorothiazide. Alisken Plus uses:
Treatment of essential hypertension in adults. Indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
Alisken Plus Tablet contains Aliskiren hemifumarate + Hydrochlorothiazide 150 mg+12.5 mg. Alisken Plus doses:
The recommended dose is one tablet per day. The antihypertensive effect is largely manifested within 1 week and the maximum effect is generallyseen within 4 weeks
Dizziness,Vertigo,Hypokalemia,Increased uric acid level ,Hyperkalemia, Diarrhea, Increased ALT , Flu-like syndrome, Cough, Weakness, Arthralgia, Diarrhea, Cough, Rash, Increased creatinine kinase, Increased BUN, Hyperkalemia, Decreased hematocrit, Decreased hemoglobin Aliskiren, Gastroesophageal reflux, Periorbital edema, Toxic epiderma necrolysis, Increased uric acid, Severe hypotension, Stevens Johnson syndrome.
Aliskiren is an orally active, potent, non-peptide and selective direct renin inhibitor used in the management of HTN. By inhibiting the enzyme renin, it prevents conversion of angiotensinogen into angiotensin I and therefore inhibits subsequent production of angiotensin II and aldosterone. Unlike ACE inhibitors and angiotensin II receptor antagonists which cause a compensatory rise in plasma renin activity, treatment with aliskiren decreases plasma renin activity and concentrations of angiotensin I angiotensin II and aldosterone .
Hydrochlorothiazide inhibits the reabsorption of Na and Cl in the distal tubules causing increased excretion of Na and water K and hydrogen ions.
Serious CHF, sodium or volume depletion. Discontinue if diarrhoea is severe and persistent. Lactation. Monitoring Parameters Periodically monitor serum potassium concentration and renal function.
Discontinue as soon as possible when pregnancy is detected; affects renin- angiotensin system causing oligohydramnios, which may result in fetal injury and/ or death.
Aliskiren increased risk of hypotension with other antihypertensives. Increased risk of acute renal failure with ACE inhibitors, angiotensin II receptor antagonists or NSAIDs. Antihypertensive effect may be reduced with NSAIDs. Increased serum levels with atorvastatin, itraconazole, ketoconazole, verapamil. Significant decrease in furosemide concentrations with aliskiren. Increased risk of hyperkalaemia with potassium-sparing diuretics, potassium supplements or any substances that may increase serum potassium levels.
Potentially Fatal: Increased risk of renal impairment, hypotension and hyperkalaemia with ACE inhibitors or angiotensin II receptor antagonists. Markedly increased plasma concentration with ciclosporin, itraconazole and quinidine.
Hydrochlorothiazide increases toxicity of lithium. May potentiate orthostatic hypotension with barbiturates and narcotics. Enhanced neuromuscular blocking action of competitive neuromuscular blockers (e.g. atracurium). Increased hypokalaemic effect with corticosteroids, corticotropin, beta 2 agonists (e.g. salbutamol). Additive effect with other antihypertensives. Potentiation of orthostatic hypotension with barbiturates or opioids. Reduced antihypertensive effect by drugs that cause fluid retention (e.g. corticosteroids, NSAIDs, carbenoxolone). Enhanced nephrotoxicity of NSAIDs. Reduced therapeutic effect of antidiabetics.
Pregnancy Category-D. Enters in breast milk; Not recommended
Elderly people (over 65 years): The recommended starting dose in elderly patients is 150 mg. No clinically meaningful additional blood pressure reduction is observed by increasing the dose to 300 mg in the majority of elderly patients.
Paediatric population: The safety and efficacy in children below 18 years have not yet been established. No data are available.
Children <2 years: Contraindicated in children from birth to less than 2 years and should not be used in children aged 2 to less than 6 years because of safety concerns due to potential aliskiren overexposure
Renal impairment: Due to the hydrochlorothiazide component, this is contraindicated for use in patients with anuria and in patients with severe renal impairment glomerular filtration rate <30 ml/min/1.73 m2 ). No adjustment of the initial dose is required for patients with mild to moderate renal impairment
Hepatic impairment: Contraindicated in patients with severe hepatic impairment and should be used with caution in patients with mild to moderate hepatic impairment or progressive liver disease. No adjustment of the initial dose is required for patients with mild to moderate hepatic impairment
Alisken Plus Tablet price in Bangladesh 0.00